New method for producing PET radiotracers in higher radiochemical yields
ANSTO researchers have led the development of a new method for producing PET radiotracers. The discovery utilises the transition metal rhenium to promote fluorine-18 radiolabelling under aqueous, low temperature conditions.
The method circumvents the need for dry conditions, and purification steps, which saves time and gives PET radiotracers in very high yields.
Fluorine-18, the most commonly used radioisotope in PET imaging, must be attached to vectors in order to diagnose disease. The best example is where fluorine-18 is attached to glucose in order to make [18F]FDG for cancer imaging.
This new method has the potential to improve production of PET radiotracers like FDG, but also facilitate development of new radiotracers by allowing previously challenging vectors to be radiolabelled in high yields under mild conditions.
Because a radiotracer decays, radio-synthesis needs to be performed quickly, efficiently and in high yield, so there is enough radiotracer to scan all patients at a PET medical centre.
"Improving methods for incorporation of fluorine-18 has been a longstanding challenge for the radiotracer community. This research is the first example of a rhenium promoted radio-fluorination, an unprecedented, exciting discovery in the radiochemistry field," said senior author Dr Benjamin Fraser, Radiotracer Method and Organic Chemistry Task leader at ANSTO.
Fraser explained that a rhenium complex was selected because of its potential for development as a dual modality PET/optical imaging agent. PET allows diagnosis of tumour location and then optical luminescence guides surgical removal of the tumour.
"The choice of rhenium proved fortuitous for the incorporation of F-18 and was good example of 'chance favouring the prepared mind' as the result was not predicted but very significant.
It's also important that the reaction can be done in water, as this simplifies subsequent formulation of the radiotracer in saline for injection into a patient in a clinical setting," said Fraser.
The study involved the use of microfluidic technologies that had several advantages for the investigation. Dr Giancarlo Pascali, co-senior investigator on the project who is based at the Camperdown cyclotron facility, supervised the radiochemistry work under microfluidic radiolabelling conditions.
"Microfluidic technologies allowed us to optimise all the reaction parameters very quickly, such as temperature, time, solvent and additives. We can optimise a given radiolabelling reaction in only three days, which under normal conditions would take one month to complete.
Another benefit of microfluidics is that we work with only very small amounts of radioactivity," said Fraser.
Fraser points out that at this stage the radiotracer has not been tested for use with PET.
"The next step is working on conjugating the tracer to new biological vectors, but also applying the new rhenium method to established radiotracers. We can then also investigate its potential use as a dual modality probe."